Preclinical Development of a Novel, Orally-Administered Anti-Tumour Necrosis Factor Domain Antibody for the Treatment of Inflammatory Bowel Disease

TNFα is an important cytokine in inflammatory bowel disease. V565 is a novel anti-TNFα domain antibody developed for oral administration in IBD patients, derived from a llama domain antibody and engineered to enhance intestinal protease resistance. V565 activity was evaluated in TNFα-TNFα receptor-b...

Descripción completa

Detalles Bibliográficos
Autores principales: Crowe, J. Scott, Roberts, Kevin J., Carlton, Timothy M., Maggiore, Luana, Cubitt, Marion F., Clare, Simon, Harcourt, Katherine, Reckless, Jill, MacDonald, Thomas T., Ray, Keith P., Vossenkämper, Anna, West, Michael R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862986/
https://www.ncbi.nlm.nih.gov/pubmed/29563546
http://dx.doi.org/10.1038/s41598-018-23277-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862986/
https://www.ncbi.nlm.nih.gov/pubmed/29563546
http://dx.doi.org/10.1038/s41598-018-23277-7

Ejemplares similares